Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Randomization completed in candesartan diabetic retinopathy program

March 3, 2004

Integrin alphavbeta3 antagonist and bone resorption inhibitor characterized for further development

March 3, 2004

Completion of extended phase I trial for Islet Neogenesis Therapy

March 2, 2004

Norditropin Nordiflex approved in Japan

March 2, 2004

CPMP hands down positive opinion for Levemir

March 2, 2004

New VPAC2 agonists in early development at Bayer

March 2, 2004

Study shows more accurate compliance for Orth Evra than oral contraceptives

March 2, 2004

MediciNova acquires KUR-1246

March 2, 2004

Aromatase inhibitors may help increase adult height in boys with CDP

March 2, 2004

New antidiabetic agents in early development at Aventis

March 1, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 27, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 26, 2026
Researchers identify innate immune barrier against melanoma
BioWorld
Australian researchers have identified a previously overlooked population of immune cells in the skin that physically restrain melanoma growth by engulfing live...
In the clinic for May 26, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: 858, A2 Biotherapeutics, AC Immune, Agendia, Agenus, Aktis, Ascentage,...
Cavalon Therapeutics and Northwestern patent new Cav1.3 blockers
BioWorld Science
Cavalon Therapeutics Inc. and Northwestern University have disclosed new voltage-gated calcium channel Cav1.3 blockers potentially useful for the treatment of...